Aytu BioPharma

141 articles about Aytu BioPharma

• Aytu BioPharma to Present on the Emerging Growth Conference on December 7, 2023

  11/30/2023

  Aytu BioPharma, Inc. today announced that its CEO, Josh Disbrow, will be participating in the Emerging Growth Conference on December 7, 2023.

• Aytu BioPharma Ranked Among Fastest-Growing Companies in North America on Deloitte's Technology Fast 500(TM) for Third Consecutive Year

  11/8/2023

  Aytu BioPharma, Inc. announced, for the third year in a row, it was included on the Deloitte Technology Fast 500™, ranking 118th among North American companies and 23rd among life sciences companies.

• Aytu BioPharma to Report First Quarter Fiscal 2024 Financial Results on November 14, 2023

  11/7/2023

  Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report financial results for its first quarter of fiscal year 2024 for the period ended September 30, 2023, after the market close on Tuesday, November 14, 2023.

• Aytu BioPharma Announces Approval of the Cotempla XR-ODT(R) Manufacturing Site Transfer Prior Approval Supplement

  10/26/2023

  Aytu BioPharma, Inc. announced receipt of U.S. Food & Drug Administration (FDA) approval of the Cotempla XR-ODT® ("Cotempla") Prior Approval Supplement (PAS).

• Aytu BioPharma to Present at Lytham Partners Fall 2023 Investor Conference on October 17, 2023

  10/9/2023

  Aytu BioPharma, Inc. (the Company or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that Josh Disbrow, Chief Executive Officer, will present and host one-on-one meetings with investors at the Lytham Partners Fall 2023 Investor Conference, taking place virtually on October 17, 2023.

• Aytu BioPharma Reports Record Revenues, Record Prescriptions, and Highest Adjusted EBITDA in Company History for the Fourth Quarter of Fiscal Year 2023

  9/26/2023

  Aytu BioPharma, Inc.announced financial and operational results for the fourth quarter and fiscal year ended June 30, 2023.

• Aytu BioPharma to Present at LD Micro Main Event XVI Conference

  9/13/2023

  Aytu BioPharma, Inc. today announced that its CEO, Josh Disbrow, and CFO, Mark Oki, will be will be participating in the LD Micro Main Event XVI Conference, being held on October 3-5, 2023, at Luxe Sunset Boulevard Hotel in Los Angeles.

• Aytu BioPharma Announces Exclusive Agreement with Medomie Pharma Ltd. to Commercialize Adzenys XR-ODT(R) and Cotempla XR-ODT(R) in Israel and the Palestinian Authority

  7/31/2023

  Aytu BioPharma, Inc. and Medomie Pharma Ltd, today announced the signing of an exclusive collaboration, distribution and supply agreement for Aytu's Adzenys XR-ODT® and Cotempla XR-ODT® product lines.

• Aytu BioPharma Announces Submission of Cotempla XR-ODT(R) Manufacturing Site Transfer Prior Approval Supplement

  7/10/2023

  Aytu BioPharma, Inc. has submitted the Cotempla XR-ODT® ("Cotempla") Prior Approval Supplement (PAS) to the U.S. Food & Drug Administration (FDA).

• Aytu BioPharma Announces Closing of $4.0 Million Public Offering Priced At-the-Market

  6/13/2023

  Aytu BioPharma, Inc. announced the closing of its equity offering co-led by Nantahala Capital Management and Stonepine Capital Management with participation by Armistice Capital of 1,743,695 shares of its common stock.

• Aytu BioPharma Reports Second Quarter of Fiscal Year 2023

  2/21/2023

  Aytu BioPharma, Inc. announced financial and operational results for the quarter ended December 31, 2022.

• Aytu BioPharma to Report Second Quarter Fiscal 2023 Financial Results on February 21, 2023

  2/21/2023

  Aytu BioPharma, Inc. will report financial results for the quarter ended December 31, 2022, after the market close , Tuesday, February 21, 2023.

• Aytu BioPharma Announces 1-for-20 Reverse Stock Split

  1/5/2023

  Aytu BioPharma, Inc., a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, announced a 1-for-20 reverse stock split of its outstanding common stock, effective at 12:01 a.m. Eastern time on January 6, 2023.

• Aytu BioPharma Announces Continuing Availability of ADHD Medication Adzenys XR-ODT(R) in Response to Reported Generic Adderall(R) XR Supply Disruptions

  10/5/2022

  Aytu BioPharma, Inc. announced the continuing availability of Adzenys XR-ODT® extended-release orally disintegrating tablets, CII in response to numerous reported supply disruptions affecting generic Adderall® XR extended-release capsule, CII for the treatment of attention deficit hyperactivity disorder.

• Aytu BioPharma Announces Closing of $10.0 Million Registered Public Offering

  8/15/2022

  Aytu BioPharma, Inc. announced the closing of its previously announced underwritten public offering of 21,505,814 shares of its common stock, and, in lieu of common stock to certain investors that so chose, pre-funded warrants to purchase 1,750,000 shares of its common stock, and accompanying warrants to purchase 23,255,814 shares of its common stock, resulting in gross proceeds of $10.0 million, assuming none of the accompanying Common Warrants issued in the Offering are exercised.

• Aytu BioPharma Announces Launch of Public Offering - Aug 08, 2022

  8/8/2022

  Aytu BioPharma, Inc. announced the launch of an underwritten public offering of shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock, and accompanying warrants to purchase its common stock.

• 

  Axsome and Aytu's Positive Day with the FDA

  4/19/2022

  Axsome Therapeutics received good news regarding its NDA for AXS-05, a treatment for depression, and Aytu BioScience received Fast Track designation for its VEDS treatment.

• Aytu BioPharma to Participate in the 34th Annual Roth Conference

  3/8/2022

  Aytu BioPharma, Inc. announced that Mark Oki, chief financial officer, and Greg Pyszczymuka, chief commercial officer of Aytu BioPharma, will participate in a fireside chat during the 34th Annual Roth Conference on Tuesday, March 15, 2022 at 2:00 p.m. PT.

• Aytu BioPharma Announces Closing of $7.6 Million Registered Offering

  3/7/2022

  Aytu BioPharma, Inc. announced the closing of its previously announced underwritten offering of 3,030,000 shares of its common stock, pre-funded warrants to purchase up to 3,030,000 shares of its common stock, and common warrants to purchase up to 6,666,000 shares of its common stock resulting in gross proceeds of $7.6 million, assuming none of the accompanying common warrants issued in the Offering are exercised.

• Aytu BioPharma Reports First Quarter 2022 Financial Results

  11/15/2021

  Aytu BioPharma, Inc., a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, reported financial results for its fiscal first quarter 2022 ended September 30, 2021.